Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lilly, Regen BioPharma in Drug Discovery Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Lilly, Regen BioPharma in Drug Discovery Pact

Regen will examine 21,000 Lilly compounds in its NR2F6 high-throughput screening program

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Regen BioPharma has entered into a definitive agreement with Eli Lilly and Co. to receive compounds from Lilly for drug discovery purposes and allows Regen to share structural information on compounds of mutual interest.

Regen will examine 21,000 Lilly compounds in its NR2F6 high-throughput screening program to identify activators and inhibitors of this protein. NR2F6 is a molecular switch known as an “orphan nuclear receptor,” which controls genes associated with the immune response as well as genes associated with the ability of cancer stem cells to propagate.  

Lilly has an option to negotiate a compound purchase agreement, a license agreement, or a research collaboration agreement for further research and development of material of mutual interest.

“Lilly’s Open Innovation Drug Discovery Program is visionary,” said Harry Lander, Ph.D., MBA, president and chief scientific officer of Regen BioPharma, Inc. “They understand the value of partnering in a confidential manner with smaller entities that may have intellectual property that aligns with their product goals.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics